Akebia Therapeutics
AKBA
#7494
Rank
S$0.52 B
Marketcap
S$2.00
Share price
-3.14%
Change (1 day)
-26.19%
Change (1 year)

Operating Margin for Akebia Therapeutics (AKBA)

Operating Margin as of December 2025 (TTM): -6.79%

According to Akebia Therapeutics's latest financial reports and stock price the company's current Operating Margin is -6.79%. At the end of 2024 the company had an Operating Margin of -43.33%.

Operating Margin history for Akebia Therapeutics from 2017 to 2025

Operating Margin at the end of each year

Year Operating Margin Change
2024-43.33%62.42%
2023-26.68%-17.18%
2022-32.22%-75.82%
2021-133.25%2.02%
2020-130.61%52.84%
2019-85.46%3.26%
2018-82.76%103.58%
2017-40.65%-99.54%
2016-8,843.45%

Operating Margin for similar companies or competitors

Company Operating Margin Operating Margin differencediff. Country
Amgen
AMGN
22.91%-437.41%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
29.12%-528.87%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Johnson & Johnson
JNJ
18.78%-376.58%๐Ÿ‡บ๐Ÿ‡ธ USA
Nektar Therapeutics
NKTR
-181.76% 2,576.88%๐Ÿ‡บ๐Ÿ‡ธ USA

What is a company's Operating Margin?

The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.